Related Experiment Video

Updated: Jan 12, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.2K

AS-IV inhibits the progression of ovarian cancer by targeting the circ_0124787/miR-6875-3p/IL-1β axis

Nan Fu1, Siyue Zhang2, Ziyi Xiao2

  • 1Department of Gynecologic Oncology, Cancer Hospital Affiliated to Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu 210009, China; Yili Kazakh Autonomous Prefecture Maternal and Child Health Hospital, Yili, Xinjiang 835100, China.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|October 30, 2025
PubMed
Abstract

Insights

Astragaloside IV (AS-IV) suppresses ovarian cancer by regulating a pathway involving circ_0124787, miR-6875-3p, and IL-1β. This mechanism reduces pro-tumorigenic γδT17 cells, highlighting a novel therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Astragaloside IV (AS-IV), a saponin from Astragalus membranaceus, exhibits anti-tumor properties.
  • Circular RNAs (circRNAs) play a role in cancer progression and are modulated by AS-IV.

Purpose of the Study:

  • To elucidate the mechanism by which AS-IV exerts anti-tumor effects in ovarian cancer.
  • To identify key circRNAs and their interactions in AS-IV's therapeutic pathway.

Main Methods:

  • Gene microarray analysis to identify differentially expressed circRNAs in ovarian cancer.
  • ELISA assays to measure IL-1β secretion.
  • Dual-luciferase reporter assays to validate circRNA-miRNA interactions.
  • Functional studies to assess the role of the circRNA-miRNA axis in AS-IV's efficacy.

Main Results:

  • Circ_0124787 was identified as a highly expressed circRNA in ovarian carcinoma.
  • Overexpression of circ_0124787 increased IL-1β secretion, promoting γδT17 cell proliferation and tumor progression.
  • Circ_0124787 functions as a competitive endogenous RNA (ceRNA) by sponging miR-6875-3p, leading to IL-1β upregulation.
  • AS-IV's anti-tumor effect is dependent on the circ_0124787/miR-6875-3p pathway.

Conclusions:

  • A novel pathway involving AS-IV, circ_0124787, miR-6875-3p, and IL-1β was identified.
  • This pathway suppresses ovarian cancer by decreasing γδT17 cell populations.
  • The findings suggest a new therapeutic strategy targeting this axis for ovarian cancer treatment.
Keywords:
AS-IVCirc_0124787IL-1βMiR-6875–3p

More Related Videos

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

3.0K
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.7K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.8K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.3K